Keyphrases
Therapeutic Target
100%
Amyotrophic Lateral Sclerosis
100%
Poly(ADP-ribose)
100%
TAR DNA-binding Protein 43 (TDP-43)
85%
Polymerase
57%
Small Molecule Inhibitors
28%
Spinal Cord
28%
Veliparib
28%
Homeostasis
14%
Motor Neuron Disease
14%
Mammalian Cells
14%
Post-translational Modification
14%
Nuclear RNA
14%
DNA-binding Proteins
14%
Therapeutic Potential
14%
Disease Progression
14%
Patient Survival
14%
Glia
14%
Phosphorylated Protein
14%
RNA-DNA
14%
Poly(ADP-ribose) Polymerase
14%
Related Disorders
14%
Neuronal Death
14%
Polymerase Activity
14%
Protein Aggregates
14%
Motor Neuron
14%
Spinal Cord Culture
14%
Neuroscience
Amyotrophic Lateral Sclerosis
100%
Poly(adenosine Diphosphate Ribose)
100%
Polymerase
83%
Veliparib
33%
Phosphoprotein
16%
Glia
16%
Posttranslational Modification
16%
Neuronal Cell Death
16%
DNA-binding Protein
16%
Motor Neuron Disease
16%
Poly ADP Ribose Polymerase
16%
Protein Aggregate
16%
TAR DNA Binding Protein
16%
Nuclear RNA
16%
Treatment of Amyotrophic Lateral Sclerosis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Amyotrophic Lateral Sclerosis
100%
Poly(adenosine Diphosphate Ribose)
100%
Veliparib
28%
Phosphoprotein
14%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
14%
Protein Aggregate
14%
DNA Binding Protein
14%
TAR DNA Binding Protein
14%
Motor Neuron Disease
14%
Nuclear RNA
14%
Diseases
14%